Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137958 | 0.84 | HDAC6 (0.53) | HDAC6KDM4EALDH1A1KMT2AMCHR1 | |
| SCHEMBL20592531 | 0.82 | HDAC6 (0.52) | HDAC6KDM4EALDH1A1KMT2AMCHR1 | |
| SCHEMBL21488666 | 0.81 | HDAC6 (0.51) | HDAC6KDM4EALDH1A1KMT2AFPR2 | |
| SCHEMBL2609928 | 0.81 | HDAC6 (0.51) | HDAC6KDM4EALDH1A1KMT2AFPR2 | |
| SCHEMBL18913971 | 0.80 | GSK3A (0.46) | KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL7641512 | 0.79 | MAPK14 (0.62) | MCHR1 | |
| SCHEMBL5023905 | 0.78 | MCL1 (0.41) | HDAC6KDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL28254025 | 0.78 | KDM4E (0.50) | HDAC6KDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL7638300 | 0.77 | HDAC6 (0.47) | HDAC6KDM4EALDH1A1MCHR1 | |
| SCHEMBL7643485 | 0.76 | HDAC6 (0.52) | HDAC6KDM4EALDH1A1MCHR1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| US-6465495-B1 | INHIBITING DISEASE STATES ASSOCIATED WITH PROTEIN PROTEIN INTERACTION MEDIATED BY A SH2 OR SH3 DOMAIN OR A TYROSINE PHOSPHATASE SUCH AS ALLERGIES, ASTHMA, ANEMIA, AUTOIMMUNE DISEASES, CANCER, INFLAMMATORY DISEASES, OSTEOPOROSIS | OSI PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | HDAC6 1437/4885KDM4E 2446/4885ALDH1A1 1527/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | HDAC6 1437/4885KDM4E 2446/4885ALDH1A1 1527/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | HDAC6 3285/4885KDM4E 1342/4885ALDH1A1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.